H.C. Wainwright analyst Douglas Tsao raised the firm’s price target on Arcutis Biotherapeutics (ARQT) to $30 from $22 and keeps a Buy rating on the shares. The company reported strong Q3 results as Zoryve again beat expectations, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARQT:
- Arcutis Biotherapeutics Reports Strong Q3 Earnings Call
- Arcutis Biotherapeutics: Strong Sales and Growth Prospects Justify Buy Rating
- Midday Fly By: OpenAI signs new Microsoft deal, PayPal reports Q3 beat
- Arcutis Biotherapeutics rises 26.5%
- Arcutis Biotherapeutics: Strong Q3 Performance and Strategic Growth Drive Buy Rating